Introduction
Pituitary adenomas (PAs) are clinically relevant endocrine tumors that account for ~10% of all intracranial neoplasms. The majority of PAs are benign, however, 30-55% are locally invasive, and a number infiltrate the dura, bone and sinuses, and are thus considered to be highly aggressive (1, 2) . The surgical treatment of aggressive PAs is often incomplete, leading to the high recurrence rate (3) . A potential treatment strategy for aggressive PAs is the targeting of tumor invasion and metastasis-associated genes.
In humans, anterior gradient 2 (AGR2) encodes the human ����l�g�� �� � ��c����� ������� ���� ��� ����� ���������� �� Xenopus laevis (4) . AGR2 has been reported to be overexpressed in several adenocarcinomas, including breast (5), colorectal (6) , ������g��l (7) , l��g (8) , ���c�����c (9) ��� �������� (10, 11) carcinomas. ARG2 is considered to promote cell proliferation, cell survival and the metastasis of cancer cells. Salmans et al ������������ ���� AGR2 �� � ���k�� �� b����� c��c�� �����-tasis and that its overexpression in estrogen receptor-positive b����� c��c�� �� ����c����� ���� � ���� ���g�����, �����c�l��l� in tumors that evade anti-hormone therapies (5) . This indicates ���� AGR2 ��� �����c����� �� ��� ���c��� �� c�ll ���������� in hormone-associated tumors. Since PAs are associated with multiple hormones in humans and as no studies have mentioned the role of AGR2 in PA, the present study investigated the expression profile of AGR2 in 117 PAs of different histological subtype by immunohistochemistry and western blotting.
Materials and methods

PA sample collection.
A total of 117 PAs of different histol�g�c�l ��b���� ���� ������l� ��l�c��� ���� �������� �g�� 17-69 ����-�l� ��� ��������� �����c���c �� ��c���c���c ����l resection between May 2013 and June 2014 in the Department of Neurosurgery, Jinling Hospital (School of Medicine, Nanjing University, Nanjing, Jiangsu, China). The study was approved by the ethics committee of Jinling Hospital and written informed consent was obtained from all patients. All resected PA tumor tissues were formalin-fixed and paraffin-embedded, and then pathologically diagnosed. The tissues consisted �� 24 ���l�c���-��c�����g ��������, 24 Immunohistochemical staining. A streptavidin-peroxidase method was used for immunostaining, as previously described (12) . Briefly, slides were deparaffinized with xylene ����� ����� (��� 5-10 ��� ��c�), ���������� ����� ����� �� � gradient series of ethanol (100, 95 and 75%), and rinsed with phosphate-buffered saline (PBS). Each slide was treated with 3% H 2 O 2 for 15 min to quench endogenous peroxidase activity. Non-specific binding was blocked by treating the slides with normal goat serum for 20 min. The slides were first incubated with rabbit anti-human monoclonal anti-AGR2 (#13062; 1:500; Cell Signaling Technology, Inc., Danvers, MA, USA) overnight at 4˚C, and then rinsed twice with PBS. The slides were then ��c�b���� ���� ��c������ ����b��� (g��� ����-��bb�� ����������� peroxidase-conjugated IgG; #BS13278; 1:5,000; Beyotime Institute of Biotechnology, Shanghai, China) for 15 min at 37˚C, followed by treatment with streptavidin-peroxidase reagent for 15 min, and were rinsed twice with PBS. The slides were visualized with 3,3'-diaminobenzidine for 3 min, counterstained with hematoxylin and mounted for microscopy.
Evaluation of staining. The slides were independently evaluated by two investigators under a light microscope (TE200; Nikon, Tokyo, Japan). As described previously (12) , the staining intensity was scored as follows: 0, negative; 1, weak; 2, medium; and 3, strong. The extent of staining was scored as follows: 0, 0%; 1, 1-25%; 2, 26-50%; 3, 51-75%; and 4, 76-100%, according to the percentages of the positive staining area in relation to the whole carcinoma area. The sum of the intensity and extent scores was used as the final staining score (range, 0-7). Tumors with a final staining score of >2 were considered to be positive. 
Results
Expression of AGR2 in PA tissues. T�� l�c����� �� AGR2 �� the nuclei was considered for scoring ( Fig. 1A-D) . The positive expression of AGR2 was detected in 60 tissues. The proportions of negative (score of ≤2) or positive (score of >2) expression in the different subtypes of PAs are shown in Table I . In total, 51.3% of all PAs exhibited AGR2 positive expression. The positive expression rate of AGR2 showed no significant differences in the PA subtypes (χ 2 =6.537; P=0.162, P<0.05), thus, the ���������� �� AGR2 c����� b� c��������� �� ���c������ �� ��� different subtypes of PAs. The western blotting data supported and confirmed the immunohistochemistry results, including high and negative expression of AGR2 in the different subtypes of PA (Fig. 2A) .
Association of AGR2 expression with clinical features of PAs.
In the 117 cases, 65 patients were male and 52 were female, with 60 patients >50 years old. The tumors were defined as Table I . Expression profile of AGR2 in different subtypes of PA. 
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follows: 70 aggressive and 47 non-aggressive PAs (according to Knosp's classification) (13); 12 recurrent and 105 primary PAs; and 13 microadenoma (diameter, ≤10 mm) and 104 macroadenoma (diameter, >10 mm). The associations between clinical variables and AGR2 expression are showed in Table II . Only the aggressiveness of PA was found to be associated with AGR2 expression (P= 0.0003, P<0.001). The majority of aggressive PAs were negative for AGR2 expression. The western blotting data also supported this result (Fig. 2B) .
Discussion
AGR2 �� ��ll ������� �� ��l�g���� ������, ��� �� ��� b��� �� our knowledge, it has never been mentioned with regard to PAs. In the present study, the expression profile was detected in 117 PA tissues of different histological subtypes for the first time. Aberrant AGR2 expression has been reported in primary breast, lung and prostate carcinomas (14) (15) (16) (17) . AGR2 overexpression in breast epithelial cell lines results in the development of metastases in an animal model (18) . However, overexpression �� ��� ��� ��l� ������ �� ���c� AGR2 c�����b���� �� ����� development (19) . The loss of AGR2 expression has also been ������������ �� b� ����c����� ���� ��� ����l����-��-c��c����� sequence in colonic polyps (20) . The present study data demonstrated that in 117 different histological subtypes of PA, 51.3% exhibited AGR2-positive expression. The positive expression rate of AGR2 showed no significant differences in the PA ��b�����, �l����g� ��� ���������� �cc����� ���� ���q����l� �� PAs secreting GH (62.5%), ACTH (80.0%) and FSH (75.0%). N���, ��� ����c������ b������ AGR2 ���������� ��� cl���c�l parameters was analyzed. Notably, the result showed that the aggressiveness of PA was associated with AGR2 expression, and that in the majority of aggressive PAs, AGR2 expression was negative. This suggested that AGR2-negative expression may be an indication for PA aggressiveness. The AGR2 protein contains a canonical cleavable N-�������l ��g��l ������� ���� ���g��� �� �� ��� ��c������ pathway (21) . The secreted proteins metastasis-associated GPI-anchored C4.4A protein and the extracellular domain �� α-dystroglycan, have been reported to directly interact ���� AGR2, ����c����g ��������l ��c������� ��� AGR2 in the promotion of tumor metastasis via the regulation of ��c����� �������� ��� ��� ������c���� ���� ��� �����c�ll�l�� matrix (17, 22) . Thus, AGR2 interacts with the cell surface in ����� �� ����l��� �������� ��� ������� ����� c�ll ���������-tion. However, by contrast, Riener et al (23) demonstrated that ��� l��� �� AGR2 ���������� �cc����� �� c�l���c��l c��c�� c�ll lines and tissue samples, which was significantly associated with a higher tumor grade and metastasis. Thus, the study ��gg����� ���� AGR2 ��� �� ����������� ���g�����c ��c��� in primary colorectal carcinoma. These results may partly support our suggestion that AGR2-negative expression may be an indication for PA aggressiveness. Numerous PAs present with aggressive characteristics, although PA is considered as a benign tumor. Aggressive PAs are usually hard to totally resect and show a tendency to recur, even after initially successful treatment (24) . Post-operative radiotherapy is always recommended to treat residual tumors and to prevent recurrence (25) . Identifying the aggressiveness of pituitary tumors is important ��� ��� ��l�c���� �� ����������� ��������� ��� ���g�����c evaluation (26) . The present study results showing that AGR2 is negative in the majority of aggressive PAs indicated that the loss of AGR2 expression may also associate with aggressive-����, ����l�� �� ��� ����l����-��-c��c����� ��q���c� �� c�l���c polyps (20) . To clarify the role of AGR2 in PA aggressiveness �� ���b� c��c�������, ������� c�ll�l�� in vitro ��� �����l in vivo experiments are necessary.
In conclusion, in the present study, 117 cases of PA of different subtypes were detected. PAs secreting GH, ACTH and FSH ���� ����� �� ������� ���� ���� ���q���� AGR2 ������-sion; however, this association was not statistically significant. The aggressiveness of PA is associated with AGR2 expression, and in the majority of aggressive PAs, AGR2 expression was negative. AGR2 may be a target for the study of PAs aggressiveness, and a potential index for the diagnosis or prognosis of PAs.
